Anti-BACE1/Tau antibody - Denali Therapeutics/Takeda

Drug Profile

Anti-BACE1/Tau antibody - Denali Therapeutics/Takeda

Alternative Names: ATV:BACE1/Tau

Latest Information Update: 23 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Denali Therapeutics Inc
  • Class Antidementias; Bispecific antibodies; Neuroprotectants
  • Mechanism of Action BACE1 protein inhibitors; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 23 Mar 2018 Denali Therapeutics intends to file an IND or CTA application in 2020
  • 05 Jan 2018 Takeda and Denali Therapeutics enter into an option and collaboration agreement to develop and commercialise therapeutics for neurodegenerative diseases
  • 01 Jan 2018 Pharmacodynamics data from a preclinical trial in Alzheimer's disease released by Denali Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top